Want to join the conversation?
$ALXN 2Q15 Call: Including Strensiq & Kanuma, company now has 8 product candidates in the clinic for 11 indications and expects at least four additional programs to enter the clinic in 2016. In late-stage pipeline, ALXN has exceeded its enrollment target in the eculizumab registration trial in refractory MG and expects preliminary data in mid-2016.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!